Myovant Sciences (MYOV) Stock Rating Lowered by ValuEngine

ValuEngine lowered shares of Myovant Sciences (NYSE:MYOV) from a buy rating to a hold rating in a report released on Saturday morning, ValuEngine reports.

Other analysts have also issued reports about the company. Zacks Investment Research raised Myovant Sciences from a hold rating to a buy rating and set a $27.00 price target on the stock in a research note on Wednesday, April 3rd. Barclays raised Myovant Sciences from an equal weight rating to an overweight rating and raised their price target for the stock from $22.00 to $25.00 in a research note on Wednesday, February 13th. JMP Securities reissued a buy rating and issued a $25.00 price target on shares of Myovant Sciences in a research note on Monday, February 11th. Finally, Evercore ISI initiated coverage on Myovant Sciences in a research note on Thursday, April 11th. They issued an outperform rating on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $30.50.

MYOV opened at $19.93 on Friday. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 2.08. The firm has a market cap of $1.45 billion, a P/E ratio of -8.27 and a beta of 0.79. Myovant Sciences has a 52 week low of $14.32 and a 52 week high of $27.45.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings data on Thursday, February 7th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.06). Equities analysts predict that Myovant Sciences will post -4.04 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of MYOV. Norges Bank acquired a new position in shares of Myovant Sciences in the 4th quarter valued at about $12,308,000. RA Capital Management LLC lifted its stake in shares of Myovant Sciences by 7.5% in the 4th quarter. RA Capital Management LLC now owns 3,711,549 shares of the company’s stock valued at $60,907,000 after purchasing an additional 259,690 shares in the last quarter. Lord Abbett & CO. LLC lifted its stake in shares of Myovant Sciences by 0.9% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,913,548 shares of the company’s stock valued at $31,401,000 after purchasing an additional 16,668 shares in the last quarter. BB Biotech AG lifted its stake in shares of Myovant Sciences by 0.8% in the 4th quarter. BB Biotech AG now owns 3,597,882 shares of the company’s stock valued at $59,041,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Myovant Sciences by 3,012.4% in the 4th quarter. Bank of New York Mellon Corp now owns 369,320 shares of the company’s stock valued at $6,060,000 after purchasing an additional 357,454 shares in the last quarter. 29.93% of the stock is currently owned by hedge funds and other institutional investors.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Story: Fundamental Analysis – How It Helps Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.